Clinical Trial Update: A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 Alone [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating afatinib plus T-DM1 versus T-DM1 alone in HER2-positive breast cancer with active brain metastases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Breast Cancer

Drugs mentioned

• Afatinib (afatinib)
• T-DM1 (ado-trastuzumab emtansine)

Snippet

Sponsor: xuexin he | Conditions: HER2-positive Breast Cancer, Brain Metastases | Phase 2 | Status: UNKNOWN